Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary outcome will be to prospectively validate a pre-treatment prognostic algorithm to predict survival for MPM patients. Secondary Outcome Measures Evaluation of Molecular Tests Base on RNA Expression [ Time Frame: 4 years ] A secondary outcome will be to evaluate molecular tests that are based ... [More >>]

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Primary Outcome Measures Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [ Time Frame: Up to 30 days ] The frequency of toxicities will be tabulated by grade across all dose levels and cycles. All subjects who receive any study treatment will be considered ... [More >>]

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events [ Time Frame: Up to 12 months ] Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only) [ Time Frame: Up to approximately 1 month ] PAD ... [More >>]

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Primary Outcome Measures Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0 [ Time Frame: 60 months ] Safety evaluation Secondary Outcome Measures Clinical response [ Time Frame: 60 months ] Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, ... [More >>]

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Primary Outcome Measures Incidence and severity of adverse events as assessed by CTCAE v.5.0 [ Time Frame: 6 weeks ] number and severity of adverse events according to NCI CTCAE v.5.0 Secondary Outcome Measures Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 6 weeks ] tumor response scored by RECIST criteria Immune-related Response Evaluation ... [More >>]

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Primary Outcome Measures Overall survival rate [ Time Frame: from randomisation to study end (the last visit for the last subject participating in the study and the last data collection point completed) assessed in up to 102 weeks ] The primary outcome measure of this study is to evaluate the overall survival ... [More >>]

Osimertinib In EGFR Mutant Lung Cancer

Primary Outcome Measures Mechanisms of resistance to Osimertinib [ Time Frame: 4 Months ] Evaluated by comparing the genomic changes using targeted next generation sequencing in the post-osimertinib tumor to the pre-treatment tumor specimen. Secondary Outcome Measures Best objective response [ Time Frame: 6 months ] Best objective response will be evaluated via RECIST 1.1 criteria. RECIST1.1 measurements of ... [More >>]

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety analysis (AEs according to CTCAE version ... [More >>]

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Primary Outcome Measures Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: 9 Months ] Establish MTD of plinabulin in combination with nivolumab and ipilimumab for patients with recurrent SCLC Phase II: Progression-Free Survival (PFS) [ Time Frame: 36 Months ] Determine if the addition of plinabulin to double checkpoint inhibition (PD-1 and CTLA-4) ... [More >>]

Hybrid APC Therapy in Early Central Lung Cancer

Primary Outcome Measures Successful remission rate: [ Time Frame: 3 months ] successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up Secondary Outcome Measures Complications [ Time Frame: 3 months ] possible complications include perforation, bleeding, fever, stenosis, cough and etc. Eligibility Criteria Inclusion Criteria Bronchoscopy and fluorescence bronchoscopy ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.